Gordana Jovic
Overview
Explore the profile of Gordana Jovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calaminus G, Jenney M, Hjorth L, Baust K, Bernstein M, Bielack S, et al.
JMIR Res Protoc
. 2019 Oct;
8(8):e14406.
PMID: 31573951
Background: The quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of...
2.
Smeland S, Bielack S, Whelan J, Bernstein M, Hogendoorn P, Krailo M, et al.
Eur J Cancer
. 2019 Jan;
109:36-50.
PMID: 30685685
Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming...
3.
Lancia C, Spitoni C, Anninga J, Whelan J, Sydes M, Jovic G, et al.
Stat Methods Med Res
. 2018 Jun;
28(9):2787-2801.
PMID: 29916309
Marginal structural models are causal models designed to adjust for time-dependent confounders in observational studies with dynamically adjusted treatments. They are robust tools to assess causality in complex longitudinal data....
4.
Kass-Iliyya A, Jovic G, Murphy C, Fisher C, Syndikus I, Jose C, et al.
Eur Urol
. 2018 Jan;
73(6):968-976.
PMID: 29307509
Background: The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain. Objective: To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation....
5.
Marina N, Smeland S, Bielack S, Bernstein M, Jovic G, Krailo M, et al.
Lancet Oncol
. 2016 Aug;
17(10):1396-1408.
PMID: 27569442
Background: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in...
6.
Langley R, Kynaston H, Alhasso A, Duong T, Paez E, Jovic G, et al.
Eur Urol
. 2015 Dec;
69(6):1016-25.
PMID: 26707868
Background: Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss....
7.
Bielack S, Smeland S, Whelan J, Marina N, Jovic G, Hook J, et al.
J Clin Oncol
. 2015 Jun;
33(20):2279-87.
PMID: 26033801
Purpose: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients And...
8.
Mason M, Parulekar W, Sydes M, Brundage M, Kirkbride P, Gospodarowicz M, et al.
J Clin Oncol
. 2015 Feb;
33(19):2143-50.
PMID: 25691677
Purpose: We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we report the prespecified final analysis of...
9.
Dearnaley D, Jovic G, Syndikus I, Khoo V, Cowan R, Graham J, et al.
Lancet Oncol
. 2014 Mar;
15(4):464-73.
PMID: 24581940
Background: The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up...
10.
Sydes M, Parmar M, Mason M, Clarke N, Amos C, Anderson J, et al.
Trials
. 2012 Sep;
13:168.
PMID: 22978443
Background: Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) is a randomized controlled trial that follows a novel multi-arm, multi-stage (MAMS) design. We describe methodological...